Use of a biosimilar granulocyte colony‐stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment

摘要: Peripheral blood haematopoietic progenitor cell mobilization has become a standard procedure prior to autologous stem transplantation. Biosimilar granulocyte colony-stimulating factors (GCSF) have recently been awarded European Union (EU) licences for but data their use in this context remain limited. The biosimilar GCSF, Ratiograstim(®) (Ratiopharm, Ulm, Germany) was granted an EU licence September 2008 and incorporated into clinical practice the Wessex Blood Marrow Transplantation Programme December 2008. Data were retrospectively collected 154 consecutive patients undergoing peripheral harvest between January 2009 2011 using GCSF. 131 from preceding 3 years, who had received Neupogen(®) , used as control. We analysed both parameters relevant collection engraftment data, where proceeded found no statistically significant difference two groups when comparing CD34 predictors, total number of CD34(+) cells collected, days required collection, or time engraftment. This is, our knowledge, largest direct comparison GCSF with originator mobilization. can produce cost saving, allowing investment other areas